Harvard Bioscience
HBIO
90 hedge funds and large institutions have $107M invested in Harvard Bioscience in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 29 increasing their positions, 30 reducing their positions, and 26 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.13% less ownership
Funds ownership: 7.32% → 7.19% (-0.13%)
3% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 30
8% less funds holding
Funds holding: 98 → 90 (-8)
19% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 26
43% less capital invested
Capital invested by funds: $187M → $107M (-$80.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2C
272 Capital
Dallas,
Texas
|
+$2.92M |
| 2 |
HP
Harvey Partners
Tarrytown,
New York
|
+$2.88M |
| 3 |
AE
AMH Equity
Great Neck,
New York
|
+$2.14M |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$1.5M |
| 5 |
Millennium Management
New York
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$8.34M |
| 2 |
State Street
Boston,
Massachusetts
|
-$2.78M |
| 3 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$2.68M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.74M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.42M |
HBIO Hedge Fund Activity: Q2 2022 in Review
90 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q2 2022, worth a combined $107M — down 43% from $187M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of HBIO and 21 opened new positions — a net loss of 5 holders — while 30 trimmed existing stakes and 29 added.
The largest buyer was 272 Capital, adding an estimated $2.92M. The largest seller was BlackRock, cutting an estimated $8.34M.
- 90 institutional investors held Harvard Bioscience (HBIO) as of Q2 2022, down from 98 in Q1 2022.
- Funds reported $107M of Harvard Bioscience stock for Q2 2022, down 43% quarter-over-quarter.
- 21 funds opened new Harvard Bioscience positions in Q2 2022 and 26 closed out, a net change of -5 holders.
- The largest Harvard Bioscience buyer in Q2 2022 was 272 Capital, an estimated $2.92M added.
- The largest Harvard Bioscience seller in Q2 2022 was BlackRock, an estimated $8.34M sold.
Based on aggregated 13F filings for Q2 2022.